Why Your GLP-1 Isn’t Working as Well Without Optimal Estrogen

The hormone connection almost no one is talking about, and the data that changes everything for women in midlife

Dr. Kristi Sawicki

Jun 09, 2026

There’s a conversation happening in functional medicine circles that hasn’t fully made it into mainstream prescribing offices yet. It goes something like this: if you’re a perimenopausal or postmenopausal woman taking a GLP-1 receptor agonist, semaglutide or tirzepatide, and you’re not seeing the results you expected, your estrogen status may be the missing variable.

This isn’t speculation. There’s now a substantial and growing body of evidence, spanning cellular biology, animal models, and human clinical data, showing that estrogen (specifically estradiol, or E2) and GLP-1 are deeply intertwined. They share receptors, influence each other’s secretion, and converge on the same metabolic pathways. Understanding this relationship doesn’t just explain why menopause is so metabolically brutal. It reframes the entire clinical conversation around GLP-1 therapy in women.

Let me walk you through the science.

What GLP-1 Actually Does (And Why Women Are Different)

GLP-1 (glucagon-like peptide-1) is an incretin hormone, a natural gut-derived signaling molecule that your intestinal L-cells and pancreatic alpha cells release in response to food. When GLP-1 binds its receptor, it stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and sends satiety signals to the hypothalamus. It is, in essence, your body’s own appetite and glucose regulation system.

GLP-1 receptor agonists (GLP-1RAs) like semaglutide and tirzepatide work by mimicking and amplifying this natural system, keeping the GLP-1 receptor activated longer and at higher levels than your body would produce on its own.

Here’s what the clinical literature has consistently shown: women lose more weight on GLP-1RAs than men across multiple large trials. This sex-based differential has been documented for exenatide, liraglutide, semaglutide, and dulaglutide. And a 2025 systematic review and meta-analysis confirmed the pattern holds broadly. The question researchers are now actively pursuing is why, and the answer is pointing directly to estrogen.

The Estradiol-GLP-1 Axis: What the Research Shows

Estradiol Directly Stimulates GLP-1 Secretion

A landmark 2018 study published in JCI Insight by Handgraaf and colleagues established a foundational finding: 17β-estradiol (E2) directly regulates GLP-1 secretion from both pancreatic alpha cells and intestinal L-cells in mouse and human tissues.

The experimental model was elegant. Researchers surgically removed the ovaries of female mice (ovariectomy = estrogen deprivation), observed the consequences, and then restored estradiol to see what was reversed. The results were clear: estrogen-deprived mice showed impaired glucose tolerance during oral glucose tolerance testing, and this was accompanied by measurably reduced GLP-1 secretion from both the gut and the pancreas. When estradiol was restored, GLP-1 secretion recovered, and glucose tolerance along with it.

The researchers went further, identifying the estrogen receptor subtypes responsible. GLP-1 secretion from alpha cells involved all three estrogen receptor isoforms (ERα, ERβ, and GPR30), while intestinal L-cell secretion was mediated primarily through ERβ. Critically, they demonstrated that a selective ERβ agonist alone was sufficient to restore glucose tolerance in ovariectomized mice, at least in part by raising circulating GLP-1. This was then validated in human alpha cells and human intestinal tissue, not just rodents.

The conclusion from this work: Estradiol is not merely correlated with GLP-1 activity. It is a direct upstream regulator of GLP-1 production and secretion.

Estrogen Upregulates GLP-1 Receptor Expression

It’s not just secretion. Estrogen also appears to enhance how well the body responds to GLP-1 by upregulating GLP-1 receptor expression in both the gastrointestinal tract and the brain, particularly in hypothalamic regions involved in appetite regulation. This means that with optimal estrogen levels, the same amount of circulating GLP-1 (whether endogenous or pharmaceutical) generates a stronger signal. More receptors = more sensitivity = more effect per dose.

This has direct clinical implications: a woman with low estrogen is not only producing less GLP-1, but she’s also responding less robustly to what she does produce, and potentially to GLP-1 medications as well.

Shared Metabolic Pathways

Estrogen and GLP-1 don’t just work in parallel — they converge on overlapping intracellular signaling pathways. Both hormones independently reduce hepatic glucose production, improve insulin sensitivity, and support lipid metabolism. Their downstream effects on glucose homeostasis involve shared cellular machinery, which is why the combination appears to produce additive — or even synergistic — metabolic outcomes rather than simply additive ones.

What Happens During Menopause

The perimenopausal and menopausal transition is defined by the progressive loss of ovarian estradiol production. The impact on metabolism is well-documented: increased visceral fat accumulation, declining insulin sensitivity, worsening lipid profiles, increased cardiovascular risk, and — critically — greater difficulty losing weight even with the same diet and exercise habits.

Now layer in what we know about the estradiol-GLP-1 axis, and you have a mechanistic explanation for a phenomenon millions of women experience but are often told is just “normal aging.”

As estradiol declines through perimenopause:

• GLP-1 secretion from intestinal L-cells and pancreatic alpha cells drops

• GLP-1 receptor sensitivity decreases

• The brain’s ability to respond to satiety signals weakens

• Hepatic glucose production loses an important hormonal check

• Insulin secretion becomes less coordinated

  
  

In other words, menopause doesn’t just alter body composition through estrogen’s direct effects on fat distribution and bone. It dismantles a key component of your endogenous appetite and glucose regulation system. You are, in a very real physiological sense, producing and responding to less of your own internal GLP-1.

This is why weight gain during menopause is so stubborn. It is not a willpower problem. It is a biochemical reality.

The Clinical Data: HRT + GLP-1 Is a Game-Changer

The mechanistic story above would be compelling on its own, but now we have meaningful human clinical data to go with it.

In March 2026, Mayo Clinic researchers published a retrospective cohort study in The Lancet Obstetrics, Gynaecology, & Women’s Health examining what happens when postmenopausal women use menopausal hormone therapy (MHT) alongside tirzepatide (Mounjaro/Zepbound).

The results were striking. Women who used hormone therapy alongside tirzepatide for at least 12 months lost approximately 35% more weight than women taking tirzepatide alone. Both groups were matched for baseline characteristics, making the difference difficult to attribute solely to confounding variables.

The study's lead author, Dr. Regina Castaneda, pointed to preclinical evidence suggesting genuine biological synergy: estrogen appears to potentiate GLP-1's appetite-suppressing effects at the receptor level. Senior author and Mayo Clinic endocrinologist Dr. Maria Daniela Hurtado Andrade was appropriately measured about causality, “this was an observational study, not a randomized trial,” but was clear that the magnitude of the difference warrants urgent follow-up in a randomized controlled design.

And this isn’t an isolated finding. Earlier work had already shown a similar synergistic effect when women combined HRT with semaglutide. The Lancet tirzepatide data fills in an important gap, extending the observation to the dual GLP-1/GIP agonist class.

There’s also an emerging hypothesis that adequate estrogen status may be protective against one of GLP-1 therapy’s most concerning side effects: loss of lean muscle mass. Research consistently shows that 25–40% of total weight lost on GLP-1RAs comes from lean tissue, not fat, a clinically significant concern, particularly for postmenopausal women who are already at risk for sarcopenia. Estrogen is a known protector of lean mass. The combination may therefore improve not just the quantity of weight lost but the quality, preserving muscle while targeting fat more effectively.

The Menstrual Cycle Dimension

The estrogen-GLP-1 relationship isn’t just relevant for postmenopausal women. Preclinical research published in late 2025 in Diabetes, Obesity and Metabolism demonstrated that the female estrous cycle (the rodent equivalent of the menstrual cycle) actively moderates GLP-1 receptor agonist efficacy. GLP-1RAs administered during the proestrus/estrus phase, the highest estrogen phase, produced significantly greater body weight loss through reduced food intake than administration during the diestrus phase. Researchers also found higher GLP-1 receptor (Glp1r) gene expression in multiple brain nuclei during the high-estrogen phase.

The translational implication: for premenopausal women, the timing of GLP-1RA administration across the menstrual cycle may actually matter for efficacy. This is an area of active investigation that could eventually inform personalized dosing protocols.

What This Means for You

If you are a perimenopausal or postmenopausal woman considering, currently using, or underperforming on a GLP-1 receptor agonist, here are the key questions to bring to your provider:

Has your estradiol been measured? Not just “are you in menopause” — but what are your actual circulating estradiol levels? Low or suboptimal E2 could be blunting your GLP-1 response before you even begin medication.

Is hormone therapy appropriate for you? The conversation around MHT has evolved considerably. For most women under 60 who are within 10 years of menopause onset and do not have contraindications, current guidelines from the Menopause Society support the use of hormone therapy. The benefits, symptom relief, cardiovascular protection, bone preservation, and now potentially metabolic synergy with GLP-1 medications, are increasingly well documented.

Is lean mass preservation part of your protocol? Whether you’re on a GLP-1RA or not, maintaining muscle mass during menopause requires intentional resistance training and adequate protein intake. If estrogen status and GLP-1 therapy are both optimization levers for body composition, resistance training is the third pillar that makes the outcomes durable.

Are you working with a provider who understands both sides of this equation? Most prescribers are operating in silos, the endocrinologist managing the GLP-1 and the gynecologist managing the hormones. The clinical picture requires someone who can see both simultaneously.

The Bottom Line

The science is clear: estrogen and GLP-1 are not independent systems. Estradiol directly stimulates GLP-1 secretion from your gut and pancreas, upregulates GLP-1 receptors in the brain and GI tract, and shares downstream metabolic pathways with GLP-1 that together govern appetite, glucose control, and fat metabolism. When estrogen declines, as it does during perimenopause and menopause, GLP-1 biology is compromised along with it.

The emerging clinical data suggests that restoring estrogen to optimal levels, when clinically appropriate, may substantially amplify the effectiveness of GLP-1 therapy, potentially by 35% or more based on the most recent Lancet data.

This is the conversation that should be happening in every prescribing office where a postmenopausal woman is handed a GLP-1 prescription. The drugs are powerful. The hormonal context in which they operate is equally important.

Precision medicine means treating the whole system, not just one variable at a time.

This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.

References

Handgraaf S, et al. 17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells. JCI Insight. 2018;3(7):e98569. PMID: 29618657

Castaneda R, et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. The Lancet Obstetrics, Gynaecology, & Women’s Health. 2026;2(2):e118. DOI: 10.1016/S3050-5038(25)00145-1

Applebey SV, et al. The estrous cycle moderates the food and body weight suppressive effects of glucagon-like peptide-1 receptor agonism. Diabetes Obes Metab. 2025. DOI: 10.1111/dom.70177

Yang Y, et al. Sex Differences in the Efficacy of GLP-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis. J Diabetes. 2025. DOI: 10.1111/1753-0407.70063

Mayo Clinic. "Women over 50 lost 35% more weight with this surprising combo." ScienceDaily. March 23, 2026. https://www.sciencedaily.com/releases/2026/03/260323005543.htm

This content is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and reflects my role as a scientist, educator, and coach — not a licensed physician. It is not a substitute for the guidance of a qualified medical provider. GLP-1 receptor agonists are FDA-approved medications; hormone therapy decisions should be made in consultation with your healthcare provider based on your individual history and risk profile.